Charter Life Sciences

Charter Life Sciences

Charter Life Sciences was founded in Mountain View, California, to invest exclusively at the intersection of biology, engineering, and data. Its origins reflect the concentration of NIH-funded research, Stanford clinical faculty, and Bay Area venture talent that makes the corridor from Palo Alto to South San Francisco the densest life-science cluster in the United States. The firm does not operate a family-office balance sheet, a hedge-fund sleeve, or a growth-buyout practice — it is a pure-play early-stage life-science investor. The firm's strategy targets preclinical and clinical-stage companies developing therapeutics, medical devices, and digital-health platforms. Charter typically participates in Seed and Series A rounds, with the capacity to follow on through later clinical milestones. Its geographic focus is overwhelmingly domestic, weighted toward California and Massachusetts — the two states that together capture more than half of all US life-science venture dollars. The firm evaluates opportunities by patent estate defensibility, the quality of the founding scientific team, and the presence of a credible lead clinician or investigator. Charter does not disclose a flagship fund name or vehicle structure publicly. The scale of Charter's commitment is observable in the life-science syndicates it joins. The firm has co-invested alongside specialized vehicles such as Arboretum Ventures and SV Health Investors in rounds where the syndicate is deliberately kept small to preserve board influence. Charter's model does not emphasize asset-gathering; its professional headcount and total committed capital are not publicly reported. No adjacent philanthropic foundation, real-asset arm, or membership-based co-investor club is known to be affiliated with the firm. Charter's structural difference is its refusal to diversify across sectors. It absorbs the binary risk of clinical trials without padding returns with software, consumer, or financial-services positions. That focus makes it a natural co-investor for larger life-science funds that need a domain-specialist voice on the board. In a market where many venture firms have added life-science pods as a diversification play, Charter operates as the inverse: a dedicated biology-first investor that declines to build a generalist platform.